Abstract.
Background: The effects of the anti-anginal drug fendiline on intracellular Ca2+ concentrations ([Ca2+]i) in human PC3 prostate cancer cells were examined. Methods: [Ca2+]i was measured using the fluorescent dye fura-2. Results: Fendiline (0.5–100 µM) increased [Ca2+]i in a concentration-dependent manner. Ca2+ removal partly inhibited the Ca2+ signals. In Ca2+-free medium, pretreatment with 100 µM fendiline inhibited most of the [Ca2+]i increase induced by 1 µM thapsigargin (an endoplasmic reticulum Ca2+ pump inhibitor), and pretreatment with thapsigargin abolished the fendiline-induced [Ca2+]i increases. Adding 3 mM Ca2+ increased [Ca2+]i in cells pretreated with 0.5–200 µM fendiline in Ca2+-free medium. Pretreatment with 1 µM U73122 to block the formation of inositol-1,4,5-trisphosphate (IP3) did not alter fendiline-induced internal Ca2+ release. Conclusions: The anti-anginal drug fendiline induced internal Ca2+ release and external Ca2+ entry. Because prolonged increases in [Ca2+]i may lead to cell injury and death, the long-term effect of fendiline on the function of prostate cancer cells should be investigated.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Jan, .C., Lee, .K., Chou, .K. et al. Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells. Cancer Chemother Pharmacol 48, 37–41 (2001). https://doi.org/10.1007/s002800000262
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800000262